Anti-angiogenic activity of Herba Epimedii on zebrafish embryos in vivo and HUVECs in vitro

Phytotherapy Research

Volumn 27, Issue 9, 2013, Pages 1368-1375

  Yu, Xiaobin ^a   Tong, Yao ^a   Han, Xiao Qiang ^b   Kwok, Hin Fai ^b   Yue, Grace Gar Lee ^b   Lau, Clara Bik San ^b   Ge, Wei ^b  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

anti angiogenesis; Herba Epimedii; HUVECs; zebrafish

Indexed keywords

ACETIC ACID ETHYL ESTER; ALCOHOL; ALKALINE PHOSPHATASE; ANGIOGENESIS INHIBITOR; BUTANOL; HERBA EPIMEDII EXTRACT; HEXANE; MITOGEN ACTIVATED PROTEIN KINASE; PLANT EXTRACT; UNCLASSIFIED DRUG; WATER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; EMBRYO; ENDOTHELIUM CELL; HERBA EPIMEDII; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MEDICINAL PLANT; NONHUMAN; NUCLEOTIDE SEQUENCE; SIGNAL TRANSDUCTION; ZEBRA FISH;

DANIO RERIO;

ANTI-ANGIOGENESIS; HERBA EPIMEDII; HUVECS; ZEBRAFISH;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DRUGS, CHINESE HERBAL; EMBRYO, NONMAMMALIAN; EPIMEDIUM; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHORYLATION; PLANT EXTRACTS; ZEBRAFISH;

EID: 84883740127     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.4881     Document Type: Article

References (50)

1. Amano M, Suzuki M, Andoh S, et al. 2007. Antiangiogenesis therapy using a novel angiogenesis inhibitor, anginex, following radiation causes tumor growth delay. Int J Clin Oncol 12: 42-47.
2. Berra E, Milanini J, Richard DE, et al. 2000. Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem Pharmacol 60: 1171-1178.
3. Cai M, Zhang H, Hui R,. 2003. Single chain Fv antibody against angiopoietin-2 inhibits VEGF-induced endothelial cell proliferation and migration in vitro. Biochem Biophys Res Commun 309: 946-951.
4. Cao J, Wang Y, Song H, et al. 2009. Hepatitis A outbreaks in China during 2006: application of molecular epidemiology. Hepatol Int 3: 356-363.
5. Cheng Y, Wang XL, Zhang DW, Wang NL, Yao XS,. 2007. Nonflavanoid compounds from Epimedium koreanum. Chin Tradit Herbal Drugs 38: 1135-1138.
6. Davis S, Aldrich TH, Jones PF, et al. 1996. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87: 1161-1169.
7. De Palma M, Venneri MA, Galli R, et al. 2005. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8: 211-226.
8. Depeille P, Young JJ, Boguslawski EA, et al. 2007. Anthrax lethal toxin inhibits growth of and vascular endothelial growth factor release from endothelial cells expressing the human herpes virus 8 viral G protein coupled receptor. Clin Cancer Res 13: 5926-5934.
9. Dong G, Chen Z, Li ZY, Yeh NT, Bancroft CC, Van Waes C,. 2001. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res 61: 5911-5918.
10. Dustin P,. 1989. The centennial of the discovery of the antimitotic properties of colchicine. Rev Med Brux 10: 385-390.
11. Ellis LM, Hicklin DJ,. 2008. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8: 579-591.
12. Etoh T, Inoue H, Tanaka S, Barnard GF, Kitano S, Mori M,. 2001. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res 61: 2145-2153.
13. Fearon U, Griosios K, Fraser A, et al. 2003. Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol 30: 260-268.
14. Ferrara N,. 1999. Molecular and biological properties of vascular endothelial growth factor. J Mol Med (Berl) 77: 527-543.
15. Folkman J,. 1995. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31.
16. Franco CA, Liebner S, Gerhardt H,. 2009. Vascular morphogenesis: a Wnt for every vessel? Curr Opin Genet Dev 19: 476-483.
17. Gallagher DC, Parikh SM, Balonov K, et al. 2008. Circulating angiopoietin 2 correlates with mortality in a surgical population with acute lung injury/adult respiratory distress syndrome. Shock 29: 656-661.
18. He MF, Huang YH, Wu LW, Ge W, Shaw PC, But PPH,. 2010. Triptolide functions as a potent angiogenesis inhibitor. Int J Cancer 126: 266-278.
19. Huang D, Ding Y, Luo WM, et al. 2008. Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. Cancer Res 68: 81-88.
20. Ingber DE, Prusty D, Sun Z, Betensky H, Wang N,. 1995. Cell shape, cytoskeletal mechanics, and cell cycle control in angiogenesis. J Biomech 28: 1471-1484.
21. Kim DW, Lu B, Hallahan DE,. 2004. Receptor tyrosine kinase inhibitors as anti-angiogenic agents. Curr Opin Investig Drugs 5: 597-604.
22. Kim I, Kwak HJ, Ahn JE, et al. 1999. Molecular cloning and characterization of a novel angiopoietin family protein, angiopoietin-3. FEBS Lett 443: 353-356.
23. Kuroda K, Sapadin A, Shoji T, Fleischmajer R, Lebwohl M,. 2001. Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. J Invest Dermatol 116: 713-720.
24. Lawson ND, Weinstein BM,. 2002. In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev Biol 248: 307-318.
25. Li GX, Zhang L, Wang Y, Mao HT, Cui ZY, Li XB, 1999. Icariin-induced apoptosis and related mechanisms in human cancer cells. Chin J Cancer Biother 6: 131-135.
26. Li L, Peng L, Miao J, et al. 2011. Icariin induces the expression of toll-like receptor 9 in ana-1 murine macrophages. Phytother Res 25: 1732-1735.
27. Lu B, Shinohara ET, Edwards E, Geng L, Tan J, Hallahan DE,. 2005. The use of tyrosine kinase inhibitors in modifying the response of tumor microvasculature to radiotherapy. Technol Cancer Res Treat 4: 691-698.
28. Mabeta P, Pepper MS,. 2009. A comparative study on the anti-angiogenic effects of DNA-damaging and cytoskeletal-disrupting agents. Angiogenesis 12: 81-90.
29. Maisonpierre PC, Suri C, Jones PF, et al. 1997. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55-60.
30. Meissner M, Pinter A, Michailidou D, et al. 2008. Microtubule-targeted drugs inhibit VEGF receptor-2 expression by both transcriptional and post-transcriptional mechanisms. J Invest Dermatol 128: 2084-2091.
31. Murphy DA, Makonnen S, Lassoued W, Feldman MD, Carter C, Lee WM,. 2006. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Am J Pathol 169: 1875-1885.
32. Nishimura M, Miki T, Yashima R, et al. 1999. Angiopoietin-3, a novel member of the angiopoietin family. FEBS Lett 448: 254-256.
33. O'Reilly MS, Boehm T, Shing Y, et al. 1997. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285.
34. Oliner J, Min H, Leal J, et al. 2004. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6: 507-516.
35. Orfanos SE, Kotanidou A, Glynos C, et al. 2007. Angiopoietin-2 is increased in severe sepsis: correlation with inflammatory mediators. Crit Care Med 35: 199-206.
36. Perona R,. 2006. Cell signalling: growth factors and tyrosine kinase receptors. Clin Transl Oncol 8: 77-82.
37. Reiss Y, Droste J, Heil M, et al. 2007. Angiopoietin-2 impairs revascularization after limb ischemia. Circ Res 101: 88-96.
38. Siner JM, Bhandari V, Engle KM, Elias JA, Siegel MD,. 2009. Elevated serum angiopoietin 2 levels are associated with increased mortality in sepsis. Shock 31: 348-353.
39. Stafford SJ, Schwimer J, Anthony CT, Thomson JL, Wang YZ, Woltering EA,. 2005. Colchicine and 2-methoxyestradiol Inhibit Human Angiogenesis. J Surg Res 125: 104-108.
40. Thomas M, Augustin HG,. 2009. The role of the Angiopoietins in vascular morphogenesis. Angiogenesis 12: 125-137.
41. Thurston G,. 2003. Role of Angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. Cell Tissue Res 314: 61-68.
42. Valenzuela DM, Griffiths JA, Rojas J, et al. 1999. Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc Natl Acad Sci USA 96: 1904-1909.
43. Wang T, Zhang JC, Chen Y, Huang F, Yang MS, Xiao PG,. 2007. Comparison of antioxidative and antitumor activities of six flavonoids from Epimedium koreanum. China J Chin Mater Med 33: 715-717.
44. Ward Y, Wang W, Woodhouse E, Linnoila I, Liotta L, Kelly K,. 2001. Signal pathways which promote invasion and metastasis: critical and distinct contributions of extracellular signal-regulated kinase and Ral-specific guanine exchange factor pathways. Mol Cell Biol 21: 5958-5969.
45. Westerfield M,. 1993. The Zebrafish Book: A Guide for the Laboratory Use of Zebrafish. University of Oregon Press: Eugene, OR.
46. Woltering EA, Lewis JM, Maxwell PJt, et al. 2003. Development of a novel in vitro human tissue-based angiogenesis assay to evaluate the effect of antiangiogenic drugs. Ann Surg 237: 790-798; discussion 798-800.
47. Yu X, Tong Y, Hin-Fai Kwok F, et al. 2012. Anti-angiogenic activity of Erxian Decoction, a traditional Chinese herbal formula, in zebrafish. Biol Pharm Bull. DOI: 10.1248/bpb.12-00130
48. Yuk SS, Lim EM, Lee JY, et al. 2010. Antiinflammatory effects of Epimedium brevicornum water extract on lipopolysaccharide-activated RAW264.7 macrophages. Phytother Res 24: 1781-1787.
49. Zhang L, Zhang X, Li KF, et al. 2012. Icariin promotes extracellular matrix synthesis and gene expression of chondrocytes in vitro. Phytother Res 26: 1385-1392.
50. Zhao Y, Cui ZY, Zhang L, Li SZ,. 1995. Inhibition of Icariin on several tumor cell proliferation by MTT assay. Shanghai J Immunol 15: 167-168